

For Immediate Release

Study using Anodyne® Therapy Published in *Endocrine Practice* Shows Consistent Improvements in Sensory Impairments due to Peripheral Neuropathy

TAMPA, FL – March 3, 2004 - Anodyne® Therapy, LLC today announced the publication of a third peer-reviewed clinical study demonstrating restoration of sensation in the feet of patients with peripheral neuropathy. This study, conducted at the Endocrine Metabolic Center by J. Joseph Prendergast, M.D. in Redwood City, CA, appears in the January/February 2004 issue of *Endocrine Practice* (the Professional Journal of the American Association of Clinical Endocrinologists).

The study shows that 26 of 27 patients showed improved nerve function using a quantitative testing device called the Neurometer CPT. Additionally, more than 59% of the patients in the study, all of whom exhibited abnormal nerve function prior to receiving treatment, obtained normal sensory response after receiving ten 40-minute treatments with Anodyne.

“We are thrilled with the publication of this additional study in *Endocrine Practice*” said Craig Turtzo, CEO. “There are now three clinical studies reported in peer reviewed medical journals that demonstrate the effectiveness of the Anodyne Therapy System in treating sensory peripheral neuropathy, a very serious and costly condition for which there had previously been no effective treatments. Together with additional studies in press, there is now clinical data on more than 2000 patients that show consistent improvements in functional limitations associated with peripheral neuropathy. These clinical studies as well as actual clinical experience has lead to wide spread acceptance of Anodyne® Therapy in the medical community.”

Peripheral neuropathy is nerve damage commonly associated with diabetes and other conditions. Symptoms include numbness and/or pain in the feet, legs and hands. Peripheral neuropathy associated with diabetes has been considered to be progressive and irreversible and the major contributing factor to chronic foot wounds, amputations and elderly falls. More than 5,000,000 people with diabetes suffer from some degree peripheral neuropathy and the related costs to the U.S. health care system have been reported to exceed \$37 billion per year.

Anodyne Therapy treatments are currently available nationwide at more than a thousand outpatient therapy facilities, hospitals, nursing homes, physician offices and home health agencies to improve functional outcomes for patients suffering from peripheral neuropathy, chronic pain and a broad range of other health problems. Products are also available for convenient home use. For more information, visit www.anodynetherapy.com.

CONTACT INFORMATION: Kim Stebbings, Vice President, Sales and Marketing
Anodyne Therapy, LLC, 13570 Wright Circle, Tampa, FL 33626
Office: 813-342-4432 ext. 122 Cell: 720-560-0533 Email: kimstebbing@aol.com